3Lin H, Boesel KM, Oriffith DT, et al. Omalizumab rapidly decreases nasal allergic response and FcepsilonRI on basophils. J Allergy Clin Immunol, 2004,113(2): 297-302.
4Fahy JV, Fleming HE, Wong HH, et al. The effect of an anti - IgE monoclonal antibody on the early - and late - phase responses to allergen inhalation in asthmatic subjects. Am J Respir Crit Care Med,1997,155(6) : 1825 - 1827.
5Boulet LP, Chapman KR, Cote J, et al. Inhibitory effects of an anti- IgE antibody on allergen - induced early asthmatic response. Am J Respir Crit Care Med, 1997,155(6) :1835 -1840.
6Bousquet J, Wenzel S, Holgate S, et al. Predicting response to omalizumab, an anti - IgE antibody, in patients with allergic asthma.Chest,2004,125(4) :1378 - 1386.
7Bousquet J, Cabrera P, Berkman N, et al. The effect of treatment with omalizumab, an anti -IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma. Allergy,2005,60(3) :302 -308.
8Strunk RC ,Bloomberg GR, Omalizumab for asthma. N Engl J Med,2006,354( 25 ) :2689 - 2695.
9Busse W, Corren J, Lanier BQ, et al. Omalizumab, an anti - IgE recombination humanized monocl onal antibody, for the treatment of severy allergic asthma. J Allergy Clin Immunol, 2001,108(2) :184 -190.
10Soler M, Matz J, Townley R, et al. The anti - IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J, 2001,18(2) :254 -261.
7Ames SA, Gleeson CD, Kirkpatrick P. Omalizumab. Nat Rev Drug Discov, 2004, 3(3 ): 199-200.
8Godse KV. Omalizumab in severe chronic urticaria. Indian J Dermatol Venereol Leprol, 2008, 74(2): 157-158.
9Lin H, Boesel KM, Griffith DT, et al. Omalizumab rapidly decreases nasal allergic response and Fc epsilonR I on basophils. J Allergy Clin Immunol, 2004, 113 (2) : 297-302.
10Chang TW, Shiung YY. Anti-IgE as a mast cell-stabilizing ther- apeutic agent. Allergy Clin lmmunol, 2006, 117(6): 1203-1212.
